Oruka Therapeutics, Inc.
ORKA
주식 순위
#3289
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
주가
$81.40
시가총액
$5.39B
변동 (1일)
1.86%
변동 (1년)
205.46%
국가
US
거래 Oruka Therapeutics, Inc. (ORKA)
카테고리
Healthcare
Oruka Therapeutics, Inc. (ORKA)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Oruka Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Oruka Therapeutics, Inc.의 P/B 비율 기록 (2005 ~ 2026)
매년 말 P/B 비율
| 연도 | P/B 비율 | 변화 |
|---|---|---|
| 2025 | 2.93 | 243.97% |
| 2024 | 0.85 | -89.28% |
| 2023 | 7.94 | -19.22% |
| 2022 | 9.83 | 39.93% |
| 2021 | 7.03 | 44.25% |
| 2020 | 4.87 | 391.44% |
| 2019 | 0.99 | 30.86% |
| 2018 | 0.76 | -44.72% |
| 2017 | 1.37 | 17.70% |
| 2016 | 1.16 | 51.58% |
| 2015 | 0.77 | -41.86% |
| 2014 | 1.32 | 42.00% |
| 2013 | 0.93 | -46.63% |
| 2012 | 1.74 | -0.42% |
| 2011 | 1.75 | -56.04% |
| 2010 | 3.98 | 27.67% |
| 2009 | 3.12 | -7,157.47% |
| 2008 | -0.04 | -103.06% |
| 2007 | 1.44 | -51.05% |
| 2006 | 2.95 | -50.04% |
| 2005 | 5.90 | 0.00% |
유사 기업 또는 경쟁사의 P/B 비율
| 회사 | P/B 비율 | P/B 비율 차이 | 국가 |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.4521 | - |
AU
|
|
| 6.3632 | - |
NL
|
|
| 3.2932 | - |
BE
|
